Literature DB >> 18754034

Genetic complexity of myeloproliferative neoplasms.

R Kralovics1.   

Abstract

Oncogenic mutations in JAK2 and MPL genes have recently been identified in myeloproliferative neoplasms (MPNs). In addition to these mutations, cytogenetic aberrations are frequently present at diagnosis but their role in the pathogenesis remains unclear. Two models of MPN pathogenesis have recently emerged based on either a single-hit or a multi-hit concept. The first model proposes that the acquisition of JAK2 mutations is the disease-initiating event, causing both the onset of disease phenotype and establishment of clonal hematopoiesis. The second model postulates the existence of 'pre-JAK2' mutations that establish clonal hematopoiesis before acquisition of JAK2 mutations and onset of disease phenotype. In this review, the two models have been critically evaluated in the context of the latest findings. At present, neither of the two models can be universally applied to all MPN patients due to their genetic heterogeneity. It is likely that the disease pathogenesis in some patients follows the first, and in other patients, the second model. Thus, the somatic mutations in MPN do not seem to be acquired in a predetermined order as seen in other malignancies, but occur randomly. Furthermore, the role of uniparental disomy in MPN and certain aspects of MPN therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18754034     DOI: 10.1038/leu.2008.233

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  34 in total

Review 1.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

2.  Molecular basis and clonal evolution of myeloproliferative neoplasms.

Authors:  Roland Jäger; Robert Kralovics
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

3.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors:  Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

4.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 5.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

6.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

7.  Two rare MPL gene mutations in patients with essential thrombocythemia.

Authors:  Haruhiko Ohashi; Kayoko Arita; Shoko Fukami; Kayo Oguri; Hirokazu Nagai; Toshiya Yokozawa; Tomomitsu Hotta; Shuichi Hanada
Journal:  Int J Hematol       Date:  2009-09-02       Impact factor: 2.490

8.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

9.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

10.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.